Novartis is making further workforce reductions at its U.S. headquarters in New Jersey, planning to eliminate 114 positions ...

The wait is over. Fierce Biotech has released its annual ranking of the top 10 pharma R&D budgets of 2025—offering a clear ...

Despite encountering a legal roadblock last month in his effort to rework the U.S. vaccine infrastructure, HHS secretary ...

Amneal and BioCorRx have earned the ire of the FDA’s Office of Prescription Drug Promotion (OPDP), with both being hit by ...

Novartis is launching a three-front push to close healthcare gaps in heart disease and cancer, expanding initiatives with the ...

Takeda ended its neurogenerative disease partnership with Denali Therapeutics. Merck & Co. and Zhifei have scrapped a minimum ...

AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount ...

Charles River Laboratories has backed an American Heart Association (AHA) campaign, joining forces with the nonprofit on ...

In connection with the deal, Assertio has divested the rest of its assets to New Jersey generics and branded drugmaker ...

As geopolitics bring reshoring interest to a fever pitch, the United States Pharmacopeia (USP) is adding to the impetus for ...

Robert F. Kennedy Jr. is starting a podcast. Unveiling the show on social media, the Department of Health and Human Services ...

Biogen has forged a settlement with investors who claimed the company misled them in describing how it gained a controversial ...